Breast Cancer Information Center
Breast cancer is the most commonly diagnosed cancer (other than skin cancer) among women in the United States. Each year, approximately 180,000 people will be diagnosed with invasive breast cancer and more than 60,000 will be diagnosed with in situ breast cancer. In order to reduce these numbers, researchers continue to explore new approaches to breast cancer prevention.
Progress is also being made in the early detection and treatment of breast cancer. Mammographic screening continues to be refined, and the use of additional screening tests, such as magnetic resonance imaging (MRI), may provide a benefit to high-risk women. Advances in surgery, radiation, and targeted therapies for breast cancer, as well as novel hormonal and chemotherapy treatment approaches, have also contributed to improved breast cancer survival. Currently, there are an estimated 2.4 million breast cancer survivors in the United States.
Other advances include improved supportive care, which makes breast cancer treatment more tolerable, and more personalized breast cancer treatment. The emerging science of genomics, for example, has made it possible to identify individuals who may not need chemotherapy.
Understanding breast cancer treatment options, the role of different doctors specializing in the treatment of breast cancer, and how and when to access new and innovative breast cancer treatment options available through clinical trials is essential in order to achieve the best outcome from breast cancer treatment.
The Cancer Consultants Breast Cancer Information Center has been designed to help patients understand options for breast cancer prevention, early detection, and treatment, while providing ongoing information, inspiration, support, and community to individuals affected by a diagnosis of breast cancer.
Headline Breast Cancer News 
Approximately 16% of Worldwide Cancers Caused By Preventable Infections
About 16% of cancers worldwide are the result of preventable and treatable infections.
Watch CancerConnect Live Web Chat with the Experts on Advances in Treatment Decision Making for Patients with Ductal Carcinoma In Situ (DCIS) May 9th at 7PM EST
Advances in Treatment Decision Making for Patients with Ductal Carcinoma In Situ-...
FDA Approves New Silicone Gel-Filled Breast Implant
The FDA has improved a silicone gel-filled breast implant manufactured by Sientra Inc.
Breast Cancer Tips
Men, Fertility, and Cancer Men who confront a cancer diagnosis before beginning or completing their families...
Women, Fertility and Cancer Women who confront a cancer diagnosis before beginning or completing their families...
What is Genomics? You’ve probably heard of genetic testing for cancer susceptibility, but the more...
Breast Cancer Management
Inspiration, Hope & Resources
Inflammatory Breast Cancer Advocacy Although breast cancer is one of the most widely covered cancers in the media and is represented by innumerable advocacy groups, inflammatory breast cancer (IBC) hasn’t historically received adequate attention
Breast Cancer Advocacy Support and Service Y-ME/Breast Cancer Network of Strength celebrates 30 years of...
Breast Cancer Advocacy 101 The National Breast Cancer Coalition knows that making a difference requires more...
Breast Cancer Conference Coverage
Advances in the Management of Breast Cancer The breast sessions at ASCO 2009 were marked by advances in prognostic and predictive markers, pharmacology, and most notably in the treatment of metastatic breast cancer...
ASCO 2008 Date: May 30-June 2, 2008 Location: Chicago, IL Bone Health ASCO 2008: Updates in...
Risk Assessment and Individualized Therapy The San Antonio Breast Cancer Symposium (SABCS) marked its 31st anniversary this year and was the first SABCS presented in collaboration by the CTRC (Cancer Therapy and Research Center at the University of Texas Health Science Center), AACR (American Association for Cancer Research)...
Breast Cancer Clinical Trials
07040 – A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in patients with ER, PR, and HER2-negative metastatic breast cancer
NU07B1 – A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer
98-04 – Phase III Trial of Observation Plus or Minus Tamoxifen VS. RT Plus or Minus Tamoxifen for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast.
 |
 |
 |
 |
